Korro Bio, Inc. (KRRO)

Korro Bio's stock has experienced notable fluctuations and analyst activity in the past six months. The stock hit a 52-week low of $11.06 around May 30, 2025. In August 2025, several analysts issued forecasts and adjusted price targets for KRRO. Raymond James Financial cut its price target to $147.00, and HC Wainwright also reduced its price target to $90.00 on August 15, 2025. Chardan Capital reaffirmed a "Buy" rating on August 15, 2025. William Blair lifted its FY2029 EPS estimates for Korro Bio on August 16, 2025, and Cantor Fitzgerald commented on the company's FY2025 earnings on August 17, 2025. On August 18, 2025, Korro Bio received an average rating of "Buy" from analysts. FY2025 EPS estimates for Korro Bio were reduced by an analyst on August 19, 2025. In late August and early September 2025, institutional investors like Aberdeen Group plc, Tri Locum Partners LP, and DAFNA Capital Management LLC made investments in Korro Bio. On September 9, 2025, the price target was decreased by 8.4% to US$92.33. On October 8, 2025, Korro Bio, Inc. announced Chief Financial Officer changes. As of October 24, 2025, the stock price was $38.09, reflecting a 1.57% gain on that day but a -11.36% loss over the preceding two weeks. The stock also holds sell signals from both short and long-term Moving Averages, suggesting a negative near-term forecast.

As a clinical-stage biopharmaceutical company, Korro Bio, Inc. does not currently have commercialized products or services that would be subject to traditional demand seasonality. Its focus is on the discovery, development, and clinical trials of genetic medicines. Therefore, demand seasonality for its products and services is not applicable at this stage of its business.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing genetic medicines through RNA editing for both rare and prevalent diseases, operating within the Healthcare sector, specifically in the Biotechnology, Drug Discovery, and Pharmaceutical Products industries. The company's core business revolves around its proprietary RNA editing platforms, Oligonucleotide Promoted Editing of RNA (OPERA) and PLEX (Programmable Landing Pad for RNA Editing), designed to precisely modify RNA sequences without altering the underlying DNA, aiming to correct disease-causing genetic mutations at the RNA level. The company's lead product candidate is KRRO-110, which is currently in Phase 1/2 clinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Korro Bio is also developing programs for other serious conditions, including Parkinson's disease, Amyotrophic lateral sclerosis (ALS), severe drug-associated anesthetics, and various pain indications, and has a collaboration agreement with Novo Nordisk A/S to develop treatments for cardiometabolic diseases.

Korro Bio, Inc. is headquartered in Cambridge, Massachusetts, United States. The clinical development of its lead product candidate, KRRO-110, is currently underway in Australia, with plans for potential expansion into other jurisdictions, including the United States.

Korro Bio's brand reputation in the past year appears to be largely influenced by its innovative RNA editing technology and its potential in treating various diseases. Analysts have generally expressed a positive sentiment, with the stock receiving "Strong Buy" ratings and optimistic price targets, driven by the potential of its technology and promising early clinical data for KRRO-110. The company's collaborations, such as with Novo Nordisk, also contribute positively to its perception. While there have been stock price volatilities and downward revisions of earnings estimates by some analysts, these are typical for clinical-stage biotech companies and do not necessarily indicate a negative shift in overall brand reputation beyond market performance. No specific events directly affecting Korro Bio's brand reputation were identified in the past year.

Korro Bio, Inc. has a significant level of institutional ownership, with 177 institutional owners and shareholders holding a total of 9,978,095 shares as of October 7, 2025. Major institutional owners include Atlas Venture Life Science Advisors, LLC, NEA Management Company, LLC, Fmr Llc, Driehaus Capital Management Llc, Point72 Asset Management, L.P., Cormorant Asset Management, LP, BlackRock, Inc., Siren, L.L.C., Vanguard Group Inc, and Qiming U.S. Ventures Management, LLC. Other notable institutional investors include Bank of America Corp DE, Raymond James Financial Inc., Walleye Capital LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., Balyasny Asset Management L.P., Franklin Resources Inc., Alliancebernstein L.P., and JPMorgan Chase & Co. The company's founders are Nessan Bermingham, Ph. D., and Winston Han, Ph. D. Insider ownership is approximately 5.4%.